Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients

International Journal of Urology : Official Journal of the Japanese Urological Association
Takeshi UedaMasayuki Maruoka

Abstract

The objective of the present study was to document the treatment efficacy and safety of sorafenib in Japanese patients with advanced renal cell carcinoma (RCC). A retrospective analysis of 50 consecutive patients with metastatic RCC between January 2005 and December 2009 was carried out. Patients received sorafenib after failed cytokine therapy or first-line sorafenib treatment. All received 400 mg of sorafenib orally twice daily. Five of 14 patients with bone metastases were also given bisphosphonates. Tumor response was evaluated every 1-2 months according to the Response Evaluation Criteria in Solid Tumors. Adverse events (AE) were evaluated at each visit during and after treatment, and were recorded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 3.0. Dose modification of sorafenib was permitted if grade 3 or 4 AE occurred. Treatment continued until disease progression or treatment intolerance occurred. Partial response, and stable disease as best objective responses were observed in 11 (22%) and 23 (46%) patients, respectively. Median progression-free survival was 7.3 months and median overall survival was 11.9 months. All patients experienced AE and one or more grade 3/4...Continue Reading

References

Sep 19, 1996·The New England Journal of Medicine·R J MotzerD M Nanus
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerJ Ferrara
May 10, 2005·Diagnostic Cytopathology·Maria Sironi, Gianni Tunesi
Dec 13, 2005·The New England Journal of Medicine·Herbert T Cohen, Francis J McGovern
Apr 26, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark J RatainPeter J O'Dwyer
Nov 8, 2006·Annals of Internal Medicine·Jayesh DesaiErik K Alexander
Jan 5, 2007·Journal of the National Cancer Institute·Brian I RiniRonald M Bukowski
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
May 1, 2007·Thyroid : Official Journal of the American Thyroid Association·Elaine WongJerome M Hershman
May 12, 2007·European Urology·Paul C M S Verhagen
Jun 15, 2007·Journal of the National Cancer Institute·Darren R FeldmanRobert J Motzer
Oct 27, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I TamaskarB I Rini
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierRonald M Bukowski

❮ Previous
Next ❯

Citations

Mar 21, 2013·Expert Opinion on Drug Safety·Daniel CastellanoJoaquim Bellmunt
Jan 29, 2016·Journal of Pharmaceutical Health Care and Sciences·Makoto KajizonoToshiaki Sendo
May 10, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Atsunari KawashimaUNKNOWN Osaka Renal Cell Carcinoma Clinical Study Collaboration
Aug 24, 2010·International Journal of Urology : Official Journal of the Japanese Urological Association·Yoshihiko Tomita
Jul 28, 2011·International Journal of Urology : Official Journal of the Japanese Urological Association·Takanobu UtsumiTomohiko Ichikawa

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
Bernard EscudierTARGET Study Group
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Bernard EscudierRonald M Bukowski
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Robert J MotzerMadhu Mazumdar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Brian I Rini
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Cora N SternbergRobert E Hawkins
© 2021 Meta ULC. All rights reserved